The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-01. Anything still debated is marked as such rather than presented as settled.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
=== Recalls === In 2006, approximately 10 million Sony batteries used in laptops were recalled, including those in laptops from Dell, Sony, Apple, Lenovo, Panasonic, Toshiba, Hitachi, Fujitsu and Sharp. The batteries were found to be susceptible to internal contamination by metal particles during manufacture. Under some circumstances, these particles could pierce the separator, causing a dangerous short circuit.
=== 3-2-1 Backup Rule === The backup data needs to be stored, requiring a backup rotation scheme, which is a system of backing up data to computer media that limits the number of backups of different dates retained separately, by appropriate re-use of the data storage media by overwriting of backups no longer needed. The scheme determines how and when each piece of removable storage is used for a backup operation and how long it is retained once it has backup data stored on it. The 3-2-1 rule can aid in the backup process. It states that there should be at least 3 copies of the data, stored on 2 different types of storage media, and one copy should be kept offsite, in a remote location (this can include cloud storage). 2 or more different media should be used to eliminate data loss due to similar reasons (for example, optical discs may tolerate being underwater while LTO tapes may not, and SSDs cannot fail due to head crashes or damaged spindle motors since they do not have any moving parts, unlike hard drives). An offsite copy protects against fire, theft of physical media (such as tapes or discs) and natural disasters like floods and earthquakes. Physically protected hard drives are an alternative to an offsite copy, but they have limitations like only being able to resist fire for a limited period of time, so an offsite copy still remains as the ideal choice. Because there is no perfect storage, many backup experts recommend maintaining a second copy on a local physical device, even if the data is also backed up offsite.
The enzyme is bifunctional and in the reverse direction is equivalent to glutathionylspermidine synthase but requires adenosine triphosphate in that case. This enzyme is a hydrolase, one acting on carbon-nitrogen bonds other than peptide bonds, specifically in linear amides. The systematic name of this enzyme class is gamma-L-glutamyl-L-cysteinyl-glycine:spermidine amidase. This enzyme is also called glutathionylspermidine amidohydrolase (spermidine-forming).
Sources: en.wikipedia.org
== Awards and honors == 2018 Elected fellow of the American Academy of Microbiology 2020 American Society for Microbiology Award for Research and Leadership in Clinical Microbiology Academy of Clinical Laboratory Physicians and Scientists Ellis S. Benson Award "40 Under 40" honoree by the American Society for Clinical Pathology
=== Others === Jessamine Lovelace — the ghost guardian of the London Institute. Also known as Jessamine Gray after her secret marriage to Tessa's brother Nate in The Infernal Devices. Jesse Blackthorn — Tatiana's deceased son and Grace Blackthorn's adoptive brother. His spirit can only be seen by his mother, Grace, and Lucie.
== History == Zalsupindole was first described in the scientific literature by David E. Olson and colleagues in 2021. It was developed by Olson's lab at the University of California, Davis and at his company Delix Therapeutics. The drug was first synthesized in 2019. It was initially described under the name AAZ-A-154 and then by the name DLX-001 before receiving the name zalsupindole.
Sources: en.wikipedia.org
== Proposed benefits == AI agents have been proposed as a means of increasing personal and economic productivity, fostering greater innovation, and liberating users from monotonous tasks. However, Parmy Olson's Bloomberg opinion piece argued that agents are best suited for narrow, repetitive tasks with low risk. Conversely, researchers suggest that agents could be applied to web accessibility for people with disabilities, and researchers at Hugging Face propose that agents could be used for coordinating resources such as during disaster response. The R&D Advisory Team of the BBC views AI agents as being most useful when their assigned goal is uncertain. Erik Brynjolfsson suggests that AI agents are more valuable in enhancing, rather than replacing, humans.
== Genetics == Mutation in the gene CAPN3, which encodes the protein calpain-3 (CAPN3), is the cause of calpainopathy. As of 2019, more than 480 CAPN3 mutations have been reported, some of which can be associated with severe or benign disease course. Usually, the disease follows an autosomal recessive inheritance pattern, requiring both CAPN3 alleles to be mutated for disease to occur. However, there can be CAPN3 mutations that follow an autosomal dominant inheritance pattern.
Calcitonin gene-related peptide 2 (CGRP2), also called calcitonin related polypeptide beta, is a hormone that in humans is encoded by the CALCB gene (previously CALC2). Like the related hormone, calcitonin gene-related peptide 1 (CGRP1), this hormone induces vasodilation (relaxation of blood vessels) through the activation of the CGRP receptor. This form of calcitonin gene-related peptide is traditionally considered to be the primary form used in the enteric nervous system (nervous system in the gut). The gene that encodes CGRP1, CALCA, also encodes the blood-calcium-reducing hormone calcitonin, but despite its name, this protein is encoded by a distinct gene (CALCB). This hormone activates the CGRP receptor, which is a two protein (heterodimer) complex that is composed of RAMP1 and CALCRL.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.